Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell
Main Authors: Wec, Anna Z., Herbert, Andrew S., Murin, Charles D., Nyakatura, Elisabeth K., Abelson, Dafna M., Fels, J. Maximilian, He, Shihua, James, Rebekah M., de La Vega, Marc-Antoine, Zhu, Wenjun, Bakken, Russell R., Goodwin, Eileen, Turner, Hannah L., Jangra, Rohit K., Zeitlin, Larry, Qiu, Xiangguo, Lai, Jonathan R., Walker, Laura M., Ward, Andrew B., Dye, John M., Chandran, Kartik, Bornholdt, Zachary A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808922/
https://ncbi.nlm.nih.gov/pubmed/28525755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2017.04.037
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados